Company Overview

Our mission is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases.

We are applying our proven proprietary technology platform, Arestat®, to develop a portfolio of superior, proprietary products that address areas of high unmet patient need in high value markets.

Our aim is to have multiple options to drive a step-change in company value for our shareholders.

 

Latest Documents

Arecor Therapeutics plc Form of Proxy

28 April 2026

Arecor Therapeutics plc Notice of Annual General Meeting

28 April 2026

Arecor Therapeutics plc Annual Report and Accounts 2025

28 April 2026

Contact: ir@arecor.com